

# Francesca Prignano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5266104/publications.pdf>

Version: 2024-02-01

160  
papers

3,084  
citations

172386

29  
h-index

233338

45  
g-index

162  
all docs

162  
docs citations

162  
times ranked

3701  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molluscum contagiosum in pediatric patients: to treat or not to treat? Could a personalized imiquimod regimen be the answer to the dilemma?. Journal of Dermatological Treatment, 2022, 33, 443-448.	1.1	3
2	Long-term safety and efficacy of anti-tumor necrosis factor-alpha biosimilar agents in the treatment of psoriasis: a single center study. Journal of Dermatological Treatment, 2022, 33, 1983-1985.	1.1	4
3	Efficacy and safety of dimethylfumarate in elderly psoriasis patients: a multicentric Italian study. Journal of Dermatological Treatment, 2022, 33, 2000-2003.	1.1	7
4	Inside-out and outside-in organotypic normal human skin culture: JAK-STAT pathway is activated after pro-inflammatory psoriatic cytokine exposure. Tissue and Cell, 2022, 74, 101675.	1.0	4
5	Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study. Expert Opinion on Biological Therapy, 2022, 22, 547-554.	1.4	8
6	The Role of Glutathione-S Transferase in Psoriasis and Associated Comorbidities and the Effect of Dimethyl Fumarate in This Pathway. Frontiers in Medicine, 2022, 9, 760852.	1.2	14
7	Identification of clinical features affecting diagnostic delay in paediatric hidradenitis suppurativa: results from a multicentre observational study. British Journal of Dermatology, 2022, 187, 428-430.	1.4	6
8	Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Italian Journal of Dermatology and Venereology, 2022, 157, 1-78.	0.1	25
9	Looking at Interleukin-22 from a New Dermatological Perspective: From Epidermal Homeostasis to Its Role in Chronic Skin Diseases. Dermatology, 2022, , 1-8.	0.9	4
10	Sharing Patient and Clinician Experiences of Moderate-to-Severe Psoriasis: A Nationwide Italian Survey and Expert Opinion to Explore Barriers Impacting upon Patient Wellbeing. Journal of Clinical Medicine, 2022, 11, 2801.	1.0	6
11	Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome. Expert Opinion on Biological Therapy, 2022, 22, 1443-1448.	1.4	9
12	Evidence for a "window of opportunity"™ in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study*. British Journal of Dermatology, 2021, 184, 133-140.	1.4	88
13	Intellectual Disability and Hidradenitis Suppurativa. Dermatology, 2021, 237, 386-388.	0.9	1
14	Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study. Clinical Rheumatology, 2021, 40, 2251-2262.	1.0	10
15	Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study. Expert Opinion on Biological Therapy, 2021, 21, 271-277.	1.4	40
16	Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars. Expert Opinion on Biological Therapy, 2021, 21, 75-80.	1.4	9
17	Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study. Acta Dermato-Venereologica, 2021, 101, adv00576.	0.6	5
18	Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis. European Journal of Dermatology, 2021, 31, 3-16.	0.3	10

#	ARTICLE	IF	CITATIONS
19	Evaluation of expression of Toll-Like Receptors 7 and 9, proliferation, and cytoskeletal biomarkers in plaque and guttate psoriasis: A pilot morphological study. <i>European Journal of Histochemistry</i> , 2021, 65, .	0.6	3
20	Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The <scp>LION</scp> real-life multicenter prospective observational cohort study. <i>Dermatologic Therapy</i> , 2021, 34, e15077.	0.8	12
21	Insights into the Pathogenesis of HS and Therapeutical Approaches. <i>Biomedicines</i> , 2021, 9, 1168.	1.4	16
22	Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. <i>Dermatology and Therapy</i> , 2021, 11, 235-252.	1.4	34
23	Risk of infections in psoriasis: assessment and challenges in daily management. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1211-1220.	1.3	2
24	Mental Health Consequences of the COVID-19 Pandemic Long-Term Exposure in Italian Dermatologists. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11239.	1.2	4
25	Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologics during the COVID-19 Pandemic. <i>Journal of Clinical Medicine</i> , 2021, 10, 5841.	1.0	3
26	Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. <i>Journal of Dermatological Treatment</i> , 2020, 31, 476-483.	1.1	23
27	Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa. <i>Dermatologic Therapy</i> , 2020, 33, e14387.	0.8	13
28	Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review. <i>Rheumatology and Therapy</i> , 2020, 7, 741-757.	1.1	37
29	Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e770-e772.	1.3	31
30	Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis. <i>PLoS ONE</i> , 2020, 15, e0237267.	1.1	19
31	Is biologic treatment of hidradenitis suppurativa during the COVID-19 pandemic different from psoriasis biologic treatment?. <i>Journal of Dermatological Treatment</i> , 2020, , 1-1.	1.1	3
32	Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real-life clinical setting in Italy: the TRANSITION study. <i>Journal of Dermatological Treatment</i> , 2020, , 1-7.	1.1	3
33	<scp>SB5</scp> adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis. <i>Dermatologic Therapy</i> , 2020, 33, e13435.	0.8	11
34	The psoriatic shift induced by interleukin 17 is promptly reverted by a specific anti-IL-17A agent in a three-dimensional organotypic model of normal human skin culture. <i>European Journal of Histochemistry</i> , 2020, 64, .	0.6	5
35	COVID -19 and psoriasis: Should we fear for patients treated with biologics?. <i>Dermatologic Therapy</i> , 2020, 33, e13434.	0.8	37
36	TNF- $\alpha$ inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 591-598.	1.3	18

#	ARTICLE	IF	CITATIONS
37	Hidradenitis suppurativa and adalimumab in the COVID-19 era. <i>European Journal of Dermatology</i> , 2020, 30, 748-749.	0.3	9
38	Optimizing a clinical guidance for diagnosis of atopic dermatitis in adults: joint recommendations of the Italian Society of Dermatology and Venereology (SIDeMaST), Italian Association of Hospital Dermatologists (ADOI), and Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA). <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 1-7.	0.8	18
39	Psoriasis and its management in women of childbearing age: tools to increase awareness in dermatologists and patients. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 434-440.	0.8	7
40	Novel Therapeutic Approaches and Targets for the Treatment of Atopic Dermatitis. <i>Current Pharmaceutical Biotechnology</i> , 2020, 22, 73-84.	0.9	7
41	Elderly psoriatic patients under biological therapies: an Italian experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 143-146.	1.3	29
42	A multicenter retrospective case-control study on Suspension of TNF-inhibitors and Outcomes in Psoriatic patients (STOP study). <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 392-399.	0.8	4
43	Tuscan consensus on the diagnosis and treatment of hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 21-24.	1.3	1
44	Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 273-275.	0.6	39
45	Risk of acute infections in psoriatic patients during biologic therapies is linked to gender. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e362-e364.	1.3	6
46	Comment on "Oral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event?" <i>JAAD Case Reports</i> , 2019, 5, 138-139.	0.4	0
47	Etanercept biosimilar <sc>SB</sc> 4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. <i>British Journal of Dermatology</i> , 2019, 180, 409-410.	1.4	17
48	Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. <i>British Journal of Dermatology</i> , 2019, 180, 1547-1548.	1.4	30
49	Clinical experience with the etanercept biosimilar SB4 in psoriatic patients. <i>International Journal of Clinical Pharmacy</i> , 2019, 41, 9-12.	1.0	14
50	Clindamycin as unique antibiotic choice in Hidradenitis Suppurativa. <i>Dermatologic Therapy</i> , 2019, 32, e12792.	0.8	11
51	Efficacy and safety of adalimumab after failure of other anti-TNF± agents for plaque-type psoriasis: clinician behavior in real life clinical practice. <i>Journal of Dermatological Treatment</i> , 2019, 30, 441-445.	1.1	5
52	Tuscan consensus on the use of UVBnb phototherapy in the treatment of psoriasis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 99-105.	0.8	5
53	Moderate-to-severe psoriasis and pregnancy: impact on fertility, pregnancy outcome and treatment perspectives. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 305-314.	0.8	19
54	The role of the dermatologist in Raynaud's phenomenon: a clinical challenge. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1120-1127.	1.3	10

#	ARTICLE	IF	CITATIONS
55	The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 2065-2072.e2.	2.0	18
56	Cutaneous hyperpigmentation induced by apremilast. <i>International Journal of Dermatology</i> , 2018, 57, 473-474.	0.5	5
57	Safety and efficacy of HCV eradication during etanercept treatment for severe psoriasis. <i>Dermatologic Therapy</i> , 2018, 31, e12614.	0.8	5
58	Lichen planus triggered by CT-P13 and recurrence during secukinumab treatment. <i>British Journal of Dermatology</i> , 2018, 178, 303-304.	1.4	11
59	First case of secukinumab successful therapy in a very elderly psoriatic patient. <i>Dermatologic Therapy</i> , 2018, 31, e12668.	0.8	4
60	Epidemiology of Psoriasis and Psoriatic Arthritis in Italy—a Systematic Review. <i>Current Rheumatology Reports</i> , 2018, 20, 43.	2.1	28
61	Secukinumab reduces plasma oxidative stress in psoriasis: A case-based experience. <i>Dermatologic Therapy</i> , 2018, 31, e12675.	0.8	6
62	Hidradenitis suppurativa and associated diseases. <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 8-17.	0.1	14
63	Soccer helps in controlling the development of psoriasis in Italian second league players. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e212-e214.	1.3	6
64	Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 774-790.	1.3	140
65	Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. <i>British Journal of Dermatology</i> , 2017, 177, e325-e326.	1.4	19
66	Sister Mary Joseph Node. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2017, 110, 473.	0.2	0
67	Reply: adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e486.	1.3	2
68	Reduction in psoriasis related pruritus during biologic therapy*. <i>Dermatologic Therapy</i> , 2017, 30, e12442.	0.8	2
69	Clinical characteristics of psoriasis in inflammatory bowel disease patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e414-e416.	1.3	3
70	Epidermal barrier reaction to an in vitro psoriatic microenvironment. <i>Experimental Cell Research</i> , 2017, 360, 180-188.	1.2	11
71	Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus. <i>Dermatologic Therapy</i> , 2017, 30, e12549.	0.8	19
72	Clinical experience with infliximab biosimilar in psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, e347-e348.	1.4	10

#	ARTICLE	IF	CITATIONS
73	Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: an uncommon adverse effect?. <i>European Journal of Dermatology</i> , 2017, 27, 667-668.	0.3	8
74	Relevance of in vitro 3-D skin models in dissecting cytokine contribution to psoriasis pathogenesis. <i>Histology and Histopathology</i> , 2017, 32, 893-898.	0.5	21
75	Tuscan consensus on the diagnosis, treatment and follow-up of moderate-to-severe psoriasis. <i>Italian Journal of Dermatology and Venereology</i> , 2017, 152, 99-108.	0.1	2
76	A Pediatric Case of Sclerodermatous Graft-versus-Host Disease Responsive to Ultraviolet A1 Phototherapy. <i>Pediatric Dermatology</i> , 2016, 33, e99-102.	0.5	4
77	Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions. <i>Clinical and Experimental Immunology</i> , 2016, 186, 364-372.	1.1	29
78	Interleukin 22 early affects keratinocyte differentiation, but not proliferation, in a three-dimensional model of normal human skin. <i>Experimental Cell Research</i> , 2016, 345, 247-254.	1.2	17
79	Vitiligo masks malignant acanthosis nigricans in a woman with ovarian cancer. <i>International Journal of Dermatology</i> , 2015, 54, 1300-1302.	0.5	5
80	Measuring psoriatic disease in clinical practice. An expert opinion position paper. <i>Autoimmunity Reviews</i> , 2015, 14, 864-874.	2.5	25
81	Cutaneous Non-Tuberculous Mycobacterial Infections: Clinical Clues and Treatment Options. <i>Current Treatment Options in Infectious Diseases</i> , 2015, 7, 352-362.	0.8	1
82	Tumor necrosis factor-alpha and interleukin-17 differently affects Langerhans cell distribution and activation in an innovative three-dimensional model of normal human skin. <i>European Journal of Cell Biology</i> , 2015, 94, 71-77.	1.6	15
83	Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. <i>Autoimmunity Reviews</i> , 2015, 14, 503-509.	2.5	150
84	Erythrodermic psoriasis treated with ustekinumab: An Italian multicenter retrospective analysis. <i>Journal of Dermatological Science</i> , 2015, 78, 149-151.	1.0	21
85	<scp>PSOCUBE</scp>, a multidimensional assessment of psoriasis patients as a both clinically/practically sustainable and evidence-based algorithm. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1310-1317.	1.3	8
86	Ultrasonographic wrist and hand abnormalities in early psoriatic arthritis patients: correlation with clinical, dermatological, serological and genetic indices. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 330-5.	0.4	19
87	Tuberculosis Reactivation Risk in Dermatology. <i>Journal of rheumatology Supplement, The</i> , 2014, 91, 65-70.	2.2	9
88	Restarting Biologics and Management of Patients with Flares of Inflammatory Rheumatic Disorders or Psoriasis During Active Tuberculosis Treatment. <i>Journal of rheumatology Supplement, The</i> , 2014, 91, 78-82.	2.2	17
89	In-vivo imaging of psoriatic lesions with polarization multispectral dermoscopy and multiphoton microscopy. <i>Biomedical Optics Express</i> , 2014, 5, 2405.	1.5	31
90	HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF- $\alpha$ ) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. <i>International Journal of Rheumatology</i> , 2014, 2014, 1-9.	0.9	57

#	ARTICLE	IF	CITATIONS
91	High frequency ultrasound can detect improvement of lesions in juvenile localized scleroderma. <i>Modern Rheumatology</i> , 2014, 24, 869-873.	0.9	38
92	<scp>SIRT</scp>1 regulates <scp>MAPK</scp> pathways in vitiligo skin: insight into the molecular pathways of cell survival. <i>Journal of Cellular and Molecular Medicine</i> , 2014, 18, 514-529.	1.6	59
93	Latent tuberculosis infection in psoriasis and other dermatological immunomediated diseases: a combined approach by <scp>Q</scp>uant<scp>FERON</scp><sup>Â®</sup>â€œ<scp>TB G</scp>old and tuberculin skin tests. <i>International Journal of Dermatology</i> , 2014, 53, e372-4.	0.5	4
94	An innovative three-dimensional model of normal human skin to study the proinflammatory psoriatic effects of tumor necrosis factor-alpha and interleukin-17. <i>Cytokine</i> , 2014, 68, 1-8.	1.4	33
95	Detection and management of latent tuberculosis infections before biologic therapy for psoriasis. <i>Journal of Dermatological Treatment</i> , 2013, 24, 305-311.	1.1	28
96	Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 511-512.	0.6	47
97	Serial QuantiFERON TB-Gold in-tube testing during LTBI therapy in candidates for TNFi treatment. <i>Journal of Infection</i> , 2013, 66, 346-356.	1.7	33
98	Possible reconsideration of the Nail Psoriasis Severity Index (NAPSI) score. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 1053-1054.	0.6	13
99	Altered redox status in the blood of psoriatic patients: involvement of NADPH oxidase and role of anti-TNF-Î± therapy. <i>Redox Report</i> , 2013, 18, 100-106.	1.4	69
100	Treatment of severe nail psoriasis with acitretin: an impressive therapeutic result. <i>Dermatologic Therapy</i> , 2013, 26, 77-78.	0.8	29
101	Fissured tongue responding to biologics during the treatment of psoriasis: the importance of detecting oral involvement of psoriasis. <i>Dermatologic Therapy</i> , 2013, 26, 364-366.	0.8	10
102	Gottron papules: a pathognomonic sign of dermatomyositis. <i>Cmaj</i> , 2013, 185, 148-148.	0.9	5
103	Induction of apoptosis by fractional CO<sub>2</sub>laser treatment. <i>Journal of Cosmetic and Laser Therapy</i> , 2012, 14, 267-271.	0.3	6
104	Efficacy of ustekinumab in sub-erythrodermic psoriasis: when TNF-blockers fail. <i>Dermatologic Therapy</i> , 2012, 25, 283-285.	0.8	13
105	Development of MGUS in psoriatic patients: a possible undiagnosed event during antiâ€œTNFâ€œ treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1444-1448.	1.3	18
106	Why is Kikuchiâ€œFujimoto disease misleading?. <i>International Journal of Dermatology</i> , 2012, 51, 564-567.	0.5	8
107	Etanercept restores a differentiated keratinocyte phenotype in psoriatic human skin: a morphological study. <i>Experimental Dermatology</i> , 2012, 21, 549-551.	1.4	15
108	Circulating dendritic cell subsets in psoriatic patients before and after biologic therapy. <i>Journal of Dermatology</i> , 2012, 39, 274-274.	0.6	1



#	ARTICLE	IF	CITATIONS
109	Mast cells do not play a role in vitiligo. <i>European Journal of Dermatology</i> , 2011, 21, 800-801.	0.3	4
110	Etanercept therapy in a hepatitis B virus (HBV)â€­positive psoriatic patient developing a monoclonal gammopathy of undetermined significance. <i>International Journal of Dermatology</i> , 2011, 50, 999-1001.	0.5	4
111	Mucosal psoriasis: a new insight toward a systemic inflammatory disease. <i>International Journal of Dermatology</i> , 2011, 50, 1579-1581.	0.5	8
112	Tumour necrosis factor-Î± antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. <i>British Journal of Dermatology</i> , 2011, 164, no-no.	1.4	52
113	A study of fractional CO2 laser resurfacing: the best fluences through a clinical, histological, and ultrastructural evaluation. <i>Journal of Cosmetic Dermatology</i> , 2011, 10, 210-216.	0.8	26
114	Intense pulsed light in the treatment of non-aesthetic facial and neck vascular lesions: report of 85 cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 68-73.	1.3	31
115	Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 549-553.	1.3	34
116	Dendritic cells: ultrastructural and immunophenotypical changes upon nb-UVB in vitiligo skin. <i>Archives of Dermatological Research</i> , 2011, 303, 231-238.	1.1	13
117	A global approach to psoriatic patients through PASI score and Skindex-29. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2011, 146, 47-52.	0.8	1
118	Juvenile psoriatic arthritis and comorbidities: report of a case associated with enthesitis and celiac disease. <i>Dermatologic Therapy</i> , 2010, 23, S47-S50.	0.8	5
119	Unusual presentation of tuberculosis in an infliximab-treated patient - which is the correct TB screening before starting a biologic?. <i>Dermatologic Therapy</i> , 2010, 23, S1-S3.	0.8	14
120	The concept of psoriatic disease: Can cutaneous psoriasis any longer be separated by the systemic comorbidities?. <i>Dermatologic Therapy</i> , 2010, 23, 119-122.	0.8	23
121	Psoriasis and body mass index. <i>Dermatologic Therapy</i> , 2010, 23, 152-154.	0.8	42
122	Retrospective analysis of systemic treatments for psoriasis patients attending a Psocare center in Florence. Relevance of biological drugs use and comorbidities. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 555-560.	1.3	7
123	Cutaneous mastocytosis: successful treatment with narrowband ultraviolet B phototherapy. <i>Clinical and Experimental Dermatology</i> , 2010, 35, 914-915.	0.6	18
124	Development of monoclonal gammopathy in 12 patients receiving efalizumab treatment for chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, e84-e87.	0.6	10
125	The Involvement of Smac/DIABLO, p53, NF-ÎºB, and MAPK Pathways in Apoptosis of Keratinocytes from Perilesional Vitiligo Skin: Protective Effects of Curcumin and Capsaicin. <i>Antioxidants and Redox Signaling</i> , 2010, 13, 1309-1321.	2.5	58
126	Systemic Immunosuppressants in the Treatment of Pruritus. , 2010, , 307-310.		2



#	ARTICLE	IF	CITATIONS
127	Exacerbation of allergic contact dermatitis during immunosuppression with cyclosporine A. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2010, 145, 543-6.	0.8	2
128	Quantity, Distribution and Immunophenotypical Modification of Dendritic Cells upon Biological Treatments in Psoriasis. <i>International Journal of Immunopathology and Pharmacology</i> , 2009, 22, 379-387.	1.0	11
129	Itch in psoriasis: epidemiology, clinical aspects and treatment options. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2009, 2, 9.	0.8	92
130	Comparison of body weight and clinical-parameter changes following the treatment of plaque psoriasis with biological therapies. <i>Current Medical Research and Opinion</i> , 2009, 25, 2311-2316.	0.9	23
131	Treatment of Psoriasis with Efalizumab in Patients with Hepatitis C Viral Infection: Report of Five Cases. <i>Dermatology</i> , 2009, 219, 158-161.	0.9	6
132	Sequential effects of photodynamic treatment of basal cell carcinoma. <i>Journal of Cutaneous Pathology</i> , 2009, 36, 409-416.	0.7	15
133	Switch from etanercept to efalizumab in a psoriatic patient with HCV infection: a case report. <i>Dermatologic Therapy</i> , 2009, 22, 386-390.	0.8	8
134	Fractional CO <sub>2</sub> laser: a novel therapeutic device upon photobiomodulation of tissue remodeling and cytokine pathway of tissue repair. <i>Dermatologic Therapy</i> , 2009, 22, S8-S15.	0.8	93
135	Ultrastructural and functional alterations of mitochondria in perilesional vitiligo skin. <i>Journal of Dermatological Science</i> , 2009, 54, 157-167.	1.0	61
136	Protease-activated receptor-2 downregulation is associated to vitiligo lesions. <i>Pigment Cell and Melanoma Research</i> , 2009, 22, 335-338.	1.5	16
137	Clinical evaluation of topical tacalcitol efficacy in extending the remission period between nb-UVB phototherapy cycles in psoriatic patients. <i>Acta Biomedica</i> , 2009, 80, 51-6.	0.2	4
138	Prurigo nodularis and lichen simplex chronicus. <i>Dermatologic Therapy</i> , 2008, 21, 42-46.	0.8	92
139	Leukocytoclastic vasculitis localized to one hemisoma in a human immunodeficiency virus-positive patient. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 1250-1252.	1.3	5
140	The importance of genetical link in immuno-mediated dermatoses: psoriasis and vitiligo. <i>International Journal of Dermatology</i> , 2008, 47, 1060-1062.	0.5	11
141	Efalizumab in the treatment of psoriasis: when comorbidity is an issue. <i>Dermatologic Therapy</i> , 2008, 21, S25-S29.	0.8	4
142	Efalizumab-induced severe thrombocytopenia can be resolved. <i>Biologics: Targets and Therapy</i> , 2008, 2, 923.	3.0	4
143	Vogt-Koyanagi-Harada disease and vitiligo: Where does the illness begin?. <i>Journal of Electron Microscopy</i> , 2007, 57, 25-31.	0.9	14
144	Therapeutical Approaches in Melasma. <i>Dermatologic Clinics</i> , 2007, 25, 337-342.	1.0	99

#	ARTICLE	IF	CITATIONS
145	A Rational Approach to the Treatment of Vitiligo and Other Hypomelanoses. <i>Dermatologic Clinics</i> , 2007, 25, 383-392.	1.0	19
146	New and Experimental Treatments of Vitiligo and Other Hypomelanoses. <i>Dermatologic Clinics</i> , 2007, 25, 393-400.	1.0	14
147	Fibrosis in regressing melanoma versus nonfibrosis in halo nevus upon melanocyte disappearance: Could it be related to a different cytokine microenvironment?. <i>Journal of Cutaneous Pathology</i> , 2007, 34, 301-308.	0.7	37
148	Stem cell factor affects tumour progression markers in metastatic melanoma cells. <i>Clinical and Experimental Metastasis</i> , 2006, 23, 177-186.	1.7	11
149	Early apoptosis plays an important role in the healing mechanism of cutaneous basal cell carcinomas after photodynamic therapy. <i>British Journal of Dermatology</i> , 2003, 149, 205-206.	1.4	10
150	Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells. <i>Cancer Letters</i> , 2002, 186, 183-192.	3.2	9
151	ATYPICAL MYCOBACTERIA. , 2001, , 88-91.		1
152	Control of the differentiation state and function of human epidermal Langerhans cells by cytokines in vitro. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2001, 15, 433-440.	1.3	7
153	Topical 5-Aminolevulinic Acid and Photodynamic Therapy in Dermatology: a Minireview. <i>Journal of Chemotherapy</i> , 2001, 13, 494-502.	0.7	33
154	Langerhans Cell Histiocytosis of the Vulva: An Ultrastructural Study. <i>Ultrastructural Pathology</i> , 1999, 23, 127-132.	0.4	6
155	Human keratinocytes cultured without a feeder layer undergo progressive loss of differentiation markers. <i>Histology and Histopathology</i> , 1999, 14, 797-803.	0.5	9
156	Immunophenotypic analysis of normal human dendritic cells isolated from epidermis and dermis. <i>International Journal of Dermatology</i> , 1998, 37, 116-119.	0.5	4
157	Traumatic eosinophilic granuloma of the oral mucosa: a CD30+(Ki-1) lymphoproliferative disorder?. <i>Oral Oncology</i> , 1997, 33, 375-379.	0.8	71
158	Cyclosporin-A affects the organization of cytoskeleton of normal human keratinocytes in culture. <i>Histology and Histopathology</i> , 1996, 11, 889-94.	0.5	7
159	CUTANEOUS METASTASIS FROM VULVAR ADENOCARCINOMA. <i>International Journal of Dermatology</i> , 1994, 33, 723-724.	0.5	3
160	CD30 +- cutaneous T-cell lymphoma associated with sarcoidosis*. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1992, 1, 103-108.	1.3	1